ArticleWorld journal of oncology2026
Association of Arylacetamide Deacetylase-Mediated Extracellular Matrix Remodeling With Immune Exclusion in Pancreatic Cancer.
Article in World journal of oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with poor prognosis, characterized by a desmoplastic tumor microenvironment (TME) that limits immune cell infiltration and diminishes response to immunotherapy. Arylacetamide deacetylase (AADAC) is a lipid-processing enzyme, but its role in tumor progression, stromal organization, and immune modulation remains unclear. Methods: We integrated single-cell RNA sequencing (GSE212966) and spatial transcriptomics (GSE235315) to evaluate the association of AADAC with extracellular matrix (ECM)-rich and immune-restrictive niches in PDAC. We performed spatial co-expression analysis, gene set variation analysis (GSVA) using a core COL6A1-ITGA2-ITGB1 signature, CellChat analysis of ligand-receptor interactions, and functional assays after AADAC knockdown in PANC-1 cells. Results: AADAC expression was significantly upregulated in PDAC epithelium and co-localized with ECM markers (COL6A1, ITGA2, ITGB1), cancer-associated fibroblast (CAF)-associated markers (podoplanin (PDPN), fibroblast activation protein (FAP)), and immunosuppressive genes ( Conclusions: AADAC expression is associated with ECM-rich and immune-restrictive tumor regions in PDAC. These findings support AADAC as a candidate biomarker of epithelial-stromal-immune interactions and justify further mechanistic studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.